Sanofi's Merial releases safe feline rabies vaccine

Sanofi's ($SNY) Merial has released what the animal health company boasts as the first nonadjuvanted feline rabies vaccine with a three-year lifespan. While other similar products have been associated with causing vaccine-related fibrosarcoma, a rare disease, Merial claims the first-of-its-kind vaccine is safe. "Veterinarians now no longer have to choose between a multiyear adjuvanted rabies vaccine and an annual nonadjuvanted rabies vaccine for clients who do not reliably return to the clinic annually," the company wrote in a statement. Article

Suggested Articles

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Pet hospital chain VCA was having a bang-up year until now, repeatedly boosting its revenue and earnings guidance, and deploying its ample cash towards buying…

The veterinary community is alarmed by the rapid increase in marijuana-related illnesses in dogs, particularly as more and more states introduce measures to…